Frontiers in Drug Discovery | Anti-Cancer Drugs

Original Research

Accepted on 21 Apr 2025

Safety and tolerability of the treatment with a bevacizumab biosimilar (Effivia ® ) in adult Mexican patients with cancer: a multicenter, observational, prospective clinical study

in Anti-Cancer Drugs

Alberto Alfonso Pimentel-Rentería
David Cantu
Eliseo Neftalí De La Cruz
David Suárez
Manuel Rodulfo Segura
José Gustavo Núñez
Livan Delgado-Roche

Frontiers in Drug Discovery

doi 10.3389/fddsv.2025.1591991

Review

Published on 29 Jan 2025

Non-enzymatic protein targeting agents as a promising strategy for cancer treatment

in Anti-Cancer Drugs

Madison Ambrose
Jeremy Lee
Aleem Syed
Zamal Ahmed
Guang Peng

Frontiers in Drug Discovery

doi 10.3389/fddsv.2025.1520734

1,285 views

Review

Published on 19 Dec 2024

Targeting steroid receptor coactivators in cancer via small molecule agents

in Anti-Cancer Drugs

Yosi Gilad
Ortal Shimon
David M. Lonard
Bert W. O’Malley

Frontiers in Drug Discovery

doi 10.3389/fddsv.2024.1514412

557 views

Review

Published on 30 Sep 2024

Combating cancer stem cells: RNA m6A methylation and small-molecule drug discovery

in Anti-Cancer Drugs

Honghai Zhang
Xueer Wang
Jianjun Chen
Rui Su

Frontiers in Drug Discovery

doi 10.3389/fddsv.2024.1465222

1,063 views
1 citation

Correction

Published on 17 Apr 2024

Corrigendum: Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

in Anti-Cancer Drugs

Xiaozhi Lv
Junyan Wu
Herui Yao
Suiwen Ye
Nan Zhang

Frontiers in Drug Discovery

doi 10.3389/fddsv.2024.1397200

681 views

Original Research

Published on 11 Apr 2024

A small molecule inhibitor of leucine carboxyl methyltransferase-1 inhibits cancer cell survival

in Anti-Cancer Drugs

O. A. Arosarena
A. S. Saribas
E. P. Papadopoulos

Frontiers in Drug Discovery

doi 10.3389/fddsv.2024.1278163

2,115 views
1 citation

Review

Published on 11 Apr 2024

A review on dynamics of permeability-glycoprotein in efflux of chemotherapeutic drugs

in Anti-Cancer Drugs

Priyanka Rani
Pranabesh Mandal
Bikash Kumar Rajak
Durg Vijay Singh

Frontiers in Drug Discovery

doi 10.3389/fddsv.2024.1363364

1,984 views
3 citations

Editorial

Published on 07 Feb 2024

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment

in Anti-Cancer Drugs

Panupong Mahalapbutr
Thanyada Rungrotmongkol

Frontiers in Drug Discovery

doi 10.3389/fddsv.2024.1365318

927 views

Original Research

Published on 22 Nov 2023

Targeting a cancer-specific LYPD3 glycoform for tumor therapy

in Anti-Cancer Drugs

Theresa Neumann
Evelyn Hartung
Johanna Gellert
Lisa Weiß
Manon Weiske
Naomi Kast
Stephanie Gurka
Sophie Marinoff
Anika Jäkel
Antje Danielczyk

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1298916

2,868 views
1 citation

Brief Research Report

Published on 03 Aug 2023

Novel mesothelin antibodies enable crystallography of the intact mesothelin ectodomain and engineering of potent, T cell-engaging bispecific therapeutics

in Anti-Cancer Drugs

Ida Lin
Peter B. Rupert
Kristina Pilat
Raymond O. Ruff
Della J. Friend
Man Kid Chan
Midori Clarke
Benjamin G. Hoffstrom
Jane Carter
Soheil Meshinchi

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1216516

4,099 views
4 citations

Original Research

Published on 07 Jul 2023

The tumor suppressor 5A2, a synthetic miR-7-5p mimic, targets oncogenic and metabolic pathways, as revealed by transcriptome-wide analysis

in Anti-Cancer Drugs

Marion T. J. van den Bosch
Bryony J. Telford
Sanaz Yahyanejad
Thijs de Gunst
Harm C. den Boer
Rogier M. Vos
Chantal L. Duurland
Rianne Biemans
Ludwig J. Dubois
Laurens A. H. van Pinxteren

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1181637

1,374 views

Original Research

Published on 09 May 2023

Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy

in Anti-Cancer Drugs

Irene Tang
Lauren Schwimmer
Shenda Gu
Wei Wei Prior
Hieu Van Tran
Allan Chan
Anna McClain
Christopher C. Fraser
Chunyan Sun
Meimei Si

Frontiers in Drug Discovery

doi 10.3389/fddsv.2023.1182146

4,159 views
1 citation

Review

Published on 06 Dec 2022

Coumarin-1,2,3-triazole hybrids as leading-edge anticancer agents

in Anti-Cancer Drugs

Krishna N. Mishra
Harish C. Upadhyay

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1072448

4,776 views
16 citations

Original Research

Published on 29 Nov 2022

ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion

in Anti-Cancer Drugs

Tao Zhang
Fang Feng
Linjiang Tong
Shingpan Chan
Yi Chen
Yan Li
Peiran Song
Yingqiang Liu
Gang Bai
Mengzhen Lai

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1050687

2,177 views

Clinical Trial

Published on 09 Sep 2022

Effect of itraconazole on the safety and pharmacokinetics of antitumor SHR6390

in Anti-Cancer Drugs

Xiaozhi Lv
Junyan Wu
Herui Yao
Suiwen Ye
Nan Zhang

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.963045

2,110 views

Brief Research Report

Published on 10 Aug 2022

Stemness inhibition by (+)-JQ1 in canine and human mammary cancer cells revealed by machine learning

in Anti-Cancer Drugs

Maycon Marção
Susanne Müller
Pedro Luiz P. Xavier
Tathiane M. Malta

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.953988

3,187 views
2 citations